Drug trials still fail to include sufficient numbers of womenBMJ 2001; 323 doi: https://doi.org/10.1136/bmj.323.7309.360/c (Published 18 August 2001) Cite this as: BMJ 2001;323:360
- Deborah Josefson
- San Francisco
Efforts to limit sex bias in clinical drug trials have improved but are still inadequate, says a follow up report on the drug approval practices of the United States' Food and Drug Administration (FDA), issued by the General Accounting Office.
The General Accounting Office is the investigative arm of the US Congress. In 1992 it found that not enough women were included in pre-approval clinical trials of drugs and charged the FDA with the task of improving …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial